Compare Neurocrine Biosciences Inc (NBIX) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs PulteGroup, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B), while PulteGroup, Inc. trades at $113.37 (market cap $21.63B). The key difference: PulteGroup, Inc. is the larger of the two by market cap, and PulteGroup, Inc. pays a 0.92% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and PulteGroup, Inc. for 91 Days on average.
| NBIX | PHM | |
|---|---|---|
Market Cap | $14.36B | $21.63B |
Volume | 1,237,180 | 2,324,729 |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $142.56 |
52-Week Low | $123.10 | $110.11 |
Typical Hold Time | 23 Days | 91 Days |
Enterprise Value | $14.37B | $22.04B |
Dividend Yield | — | 0.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
PulteGroup (PHM) trades at $112.33, down 3.25% amid broader housing sector pressure from rising mortgage rates. The stock shows bearish technical signals with recent earnings misses but maintains solid fundamentals including an 11.47 P/E ratio and 14.9% ROE. Cash flow remains positive at $355 million for 2025, though revenue and margins have softened from 2024 peaks. The company continues dividend payments with a $0.26 quarterly payout scheduled for October 2026.
PHM presents a mixed outlook with attractive valuation metrics offset by near-term headwinds. The consensus price target of $139.80 suggests 24% upside potential, but rising interest rates pose significant risk to housing demand. Investors face tension between Wall Street's bullish price targets and current technical weakness, requiring careful monitoring of Q3 2026 earnings due October 22nd for directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
